Journal of the American Academy of Child & Adolescent Psychiatry
ArticlesOpen Trial of Risperidone in 24 Young Children With Pervasive Developmental Disorders
Section snippets
Subjects
All children aged between 3 and 6.11 years referred to our Division of Child Neurology and Psychiatry as inpatients or outpatients during 1999 and 2000 were screened for psychiatric disorders; historical information, clinical interviews, and symptom ratings according to DSM-IV criteria (American Psychiatric Association, 1994) were used. Our clinic is a university research hospital with a national catchment for children and adolescents with a wide range of neuropsychiatric disorders. The
RESULTS
Two subjects did not complete the study, as parents requested discontinuation of the treatment because of side effects. After 2 weeks of treatment one child experienced marked sedation and hyporexia. Before discontinuing treatment, the child's parents had reported an improvement in self-injurious behaviors, which worsened again when the medication was interrupted. The parents of the other child decided to discontinue risperidone after 7 days of treatment (dosage 0.25 mg/day) because of episodes
DISCUSSION
The aim of this study was to assess the efficacy and safety of risperidone monotherapy in children with PDD. The age range (3.6–6.6 years) and mean age (4.6 ± 0.8 years) of these patients is significantly lower than in previous case series. Rating scales including multiple items were used in this study (CPRS and CARS), and both total score and individual item scores were considered. Although multiple statistical analyses, in the search for the treatment effect, required “a high statistical
REFERENCES (43)
- et al.
Risperidone in adolescents with schizophrenia: an open pilot study
J Am Acad Child Adolesc Psychiatry
(1997) - et al.
Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study
J Am Acad Child Adolesc Psychiatry
(1997) - et al.
Pharmacokinetics and safety of risperidone in autistic children (abstract)
Pediatr Neurol
(1994) - et al.
Effects of atypical antipsychotic agents on social behavior in rodents
Pharmacol Biochem Behav
(1993) - et al.
A scale for rating symptoms of patients with the syndrome of autism in real life settings
J Am Acad Child Psychiatry
(1986) - et al.
Psychoactive medication prescribing practices for US children: gaps between research and clinical practice
J Am Acad Child Adolesc Psychiatry
(1999) - et al.
Case study: risperidone-induced hepatotoxicity in pediatric patients
J Am Acad Child Adolesc Psychiatry
(1997) - et al.
Risperidone treatment of children and adolescents with pervasive developmental disorder: a prospective, open-label study
J Am Acad Child Adolesc Psychiatry
(1997) - et al.
Research Units on Pediatric Psychopharmacology (RUPP)-Autism Network: background and rationale for an initial controlled study of risperidone
Child Adolesc Psychiatr Clin N Am
(2000) - et al.
Use of the Childhood Autism Rating Scale with adolescents and adults
J Am Acad Child Adolesc Psychiatry
(1989)
An open trial af risperidone in young autistic children
J Am Acad Child Adolesc Psychiatry
Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration
J Am Acad Child Adolesc Psychiatry
An effective day treatment model for young children with pervasive developmental disorders
J Am Acad Child Adolesc Psychiatry
Seizure disorders in autism
J Am Acad Child Adolesc Psychiatry
Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review
Pediatrics
Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)
The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children
J Autism Dev Disord
Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network
J Autism Dev Disord
Behavioral and cognitive measures used in psychopharmacological studies of infantile autism
Psychopharmacol Bull
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
J Clin Psychopharmacol
Domains of the Childhood Autism Rating Scale: relevance for diagnosis and treatment
J Autism Dev Disord
Cited by (103)
The psychopharmacology of autism spectrum disorder and Rett syndrome
2019, Handbook of Clinical NeurologyCitation Excerpt :Risperidone, a potent antagonist at dopamine D2 and serotonin 5-HT2A receptors, has been one of the most extensively studied medications in ASD. Several open studies have supported the efficacy, safety, and tolerability of risperidone in the treatment of autistic behaviors, irritability, aggression, and hyperactivity (Findling et al., 1997; McDougle et al., 1997; Nicolson et al., 1998; Masi et al., 2001; Nishimura et al., 2003; Gagliano et al., 2004; Kent et al., 2013a,b; Lamberti et al., 2016). Multiple RCTs have also produced definitive evidence of efficacy on irritability and suggestive evidence for repetitive behaviors.
Efficacy of Risperidone in Managing Maladaptive Behaviors for Children With Autistic Spectrum Disorder: A Meta-Analysis
2012, Journal of Pediatric Health CareGroup-Based Trajectory Modeling to Identify Patterns of Antipsychotic-Associated Weight Gain Among Children and Adolescents
2024, Journal of Clinical PsychopharmacologyEfficacy of Risperidone and Methylphenidate for Problem Behaviors and Core Symptoms in Autism Spectrum Disorder: A Randomized Trial
2022, Journal of Indian Association for Child and Adolescent Mental Health